Sanofi Pasteur and US Merck to End Vaccines JV

France’s Sanofi Pasteur and Merck of the US have announced plans to end their 50:50 European vaccines joint venture, Sanofi Pasteur MSD, by the end of 2016 and manage their vaccine product portfolios independently.

More than 100 jobs at the headquarters in Lyon, France, will be affected.

The jv, with 2015 sales of €824 million, was created in 1994 to combine the two companies’ research and manufacturing capabilities and develop and commercialize vaccines from the respective pipelines in 19 European countries.

In its 20-year lifespan, Sanofi Pasteur MSD – outside the US and Canada, Merck is known as MSD – has launched or provided vaccines to protect against a range of diseases, including human papillomavirus disease, hepatitis A and B, herpes zoster, rabies, polio, typhoid fever and pneumococcal diseases.

Not all of the vaccines are available in all of the 19 EU countries served and trade names vary.

After carefully considering their individual strategic priorities, as well as the economic and regulatory environments for vaccine operations in the EU, the partners said they had decided it was in their best interest to manage the portfolios independently. This, they added would better position each to drive growth and optimize vaccine coverage.

Interview

Innovation at the Intersection of AI
Digital Potential in Key Business Areas

Innovation at the Intersection of AI

Stefan Guertzgen spoke with John Banovetz, Chief Technology Officer at 3M, about the role of digital transformation in achieving the company's objectives.

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis

most read

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.

Photo
08.11.2024 • News

Future Prospects in Green Chemistry

The Discourse on Green Chemistry Interactive Pitch Competition, held on November 5, 2024, at Wiley's Berlin office as part of Berlin Science Week, showcased a range of innovative projects aimed at addressing critical environmental challenges.

Photo
24.01.2025 • News

CEFIC Publishes 2024 Facts and Figures Report

CEFIC , the European Chemical Industry Council, has published its 2024 Facts & Figures report, which reinforces the need to take bold and urgent action to secure Europe’s industrial future, not only to implement the Green Deal but also to prevent further de-industrialization in Europe.